Optimizing Treatment for High Risk Prostate Cancer Using Hypofractionated Pelvic Radiotherapy with Tumor Boost and Reduced Hormone Therapy

What this Trial Is About

Researchers are evaluating a combined treatment approach for men with high risk prostate cancer to determine if it is safe to use several optimized therapies together. This includes delivering a higher dose of radiation to the tumor while irradiating the prostate and lymph nodes more intensively but with fewer hospital visits. The study aims to reduce androgen deprivation therapy as much as possible to minimize side effects while comparing cancer outcomes and treatment toxicity. The treatment being studied involves hypo fractionated pelvic radiotherapy with a focal boost to the primary tumor in the prostate, along with elective lymph node irradiation and minimized use of androgen deprivation therapy. This approach combines recent advances shown to improve outcomes individually but not previously combined into one comprehensive treatment. The study is designed as a prospective cohort with a matched control group. Participants will undergo regular clinical follow-up without additional tests or visits beyond standard care. Researchers will assess biochemical recurrence-free survival over 5 years and monitor late gastrointestinal and genitourinary side effects, including erectile dysfunction, at 6 months and 2 years. Secondary outcomes include metastasis-free survival, overall survival, and patterns of cancer recurrence. The estimated risks from combining these treatments are considered very limited, and the overall burden for participants is low.

Towards Optimal Treatment for High Risk Prostate Cancer